BridgeBio Pharma, Inc. (BBIO)
78.17
-1.37
(-1.72%)
USD |
NASDAQ |
Nov 12, 16:00
78.40
+0.23
(+0.29%)
After-Hours: 07:32
BridgeBio Pharma Shareholders Equity (Quarterly) : -1.662B for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -1.662B |
| June 30, 2026 | -2.515B |
| March 31, 2026 | -2.278B |
| December 31, 2025 | -2.087B |
| September 30, 2025 | -1.933B |
| June 30, 2025 | -1.788B |
| March 31, 2025 | -1.648B |
| December 31, 2024 | -1.468B |
| September 30, 2024 | -1.230B |
| June 30, 2024 | -1.093B |
| March 31, 2024 | -1.050B |
| December 31, 2023 | -1.354B |
| September 30, 2023 | -1.208B |
| June 30, 2023 | -1.362B |
| March 31, 2023 | -1.226B |
| December 31, 2022 | -1.255B |
| Date | Value |
|---|---|
| September 30, 2022 | -1.138B |
| June 30, 2022 | -1.026B |
| March 31, 2022 | -1.041B |
| December 31, 2021 | -870.41M |
| September 30, 2021 | -743.40M |
| June 30, 2021 | -464.29M |
| March 31, 2021 | -395.29M |
| December 31, 2020 | 57.91M |
| September 30, 2020 | 163.76M |
| June 30, 2020 | 265.76M |
| March 31, 2020 | 380.72M |
| December 31, 2019 | 408.45M |
| September 30, 2019 | 459.76M |
| June 30, 2019 | -316.12M |
| March 31, 2019 | -226.90M |
| December 31, 2018 | -163.99M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Ionis Pharmaceuticals, Inc. | 393.64M |
| Pfizer Inc. | 89.00B |
| Cytokinetics, Inc. | -321.17M |
| Vertex Pharmaceuticals, Inc. | 20.91B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.162B |
| Total Liabilities (Quarterly) | 3.815B |
| Debt to Equity Ratio | -2.054 |
| Current Ratio | 2.092 |
| Net Debt Paydown Yield | -1.14% |